Evidence map›Paper›PMID 25147764›Full record

ReviewTranslational medicine @ UniSa2014

Molecular biology of gliomas: present and future challenges.

R Altieri, A Agnoletti, F Quattrucci, D Garbossa, F M Calamo Specchia, M Bozzaro, R Fornaro, C Mencarani, M Lanotte, R Spaziante and 1 more

Open access · greenAbstract readReview
In one paragraph

Review in Translational medicine @ UniSa, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Association betweenOncology letters · 2018
    Article
  11. Article
  12. Article
  13. Article
  14. Concurrent activation of βCellular signalling · 2017
    Article
  15. Article
  16. Article
  17. Article
  18. A critical overview of long non-coding RNA in glioma etiology 2016: an update.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

R AltieriDepartment of Neurosurgery, University of Turin.
A AgnolettiDepartment of Neurosurgery, University of Turin.
F QuattrucciDepartment of Medicine, University of Salerno.
D GarbossaDepartment of Neurosurgery, University of Turin.
F M Calamo SpecchiaDepartment of Neurosurgery, University of Turin.
M BozzaroDepartment of Neurosurgery, University of Turin.
R FornaroDepartment of Neurosurgery, University of Turin.
C MencaraniDepartment of Neurosurgery, University of Turin.
M LanotteDepartment of Neurosurgery, University of Turin.
R SpazianteDepartment of Medicine, University of Salerno.
A DucatiDepartment of Neurosurgery, University of Turin.
University of Salerno · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malignant brain tumours are one of the most relevant causes of morbidity and mortality across a wide range of individuals. Malignant glioma is the most common intra axial tumor in the adult. Many researches on this theme brought advances in the knowledge of gliomas biology and pathogenesis and to the development of new agents for targeted molecular therapy. Recent studies focused on either tumor metabolism analysis or epigenetic regulation in the pathogenesis or maintenance of brain tumors. This Review summarizes these developments analyzing molecular pathology and possible further developments for targeted therapies.

Indexed as

geneticsgliomaIDHmetilationtherapy

Identifiers

PMID25147764
PMCPMC4140427
OpenAlexW2147239833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.